Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.

  • Allogene Therapeutics' Income from Continuing Operations rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Per Allogene Therapeutics' latest filing, its Income from Continuing Operations stood at -$41.3 million for Q3 2025, which was up 18.82% from -$50.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Income from Continuing Operations' 5-year high stood at $1.9 million during Q4 2021, with a 5-year trough of -$97.0 million in Q1 2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$64.1 million (2024), whereas its average is -$65.0 million.
  • In the last 5 years, Allogene Therapeutics' Income from Continuing Operations skyrocketed by 102.76% in 2021 and then plummeted by 5,046.54% in 2022.
  • Allogene Therapeutics' Income from Continuing Operations (Quarterly) stood at $1.9 million in 2021, then plummeted by 5,046.54% to -$93.6 million in 2022, then grew by 15.80% to -$78.8 million in 2023, then rose by 27.02% to -$57.5 million in 2024, then surged by 36.60% to -$41.3 million in 2025.
  • Its Income from Continuing Operations stands at -$41.3 million for Q3 2025, versus -$50.9 million for Q2 2025 and -$59.8 million for Q1 2025.